1. Home
  2. VATE vs ICCC Comparison

VATE vs ICCC Comparison

Compare VATE & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo INNOVATE Corp.

VATE

INNOVATE Corp.

N/A

Current Price

$7.86

Market Cap

103.5M

Sector

Industrials

ML Signal

N/A

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

N/A

Current Price

$9.98

Market Cap

93.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VATE
ICCC
Founded
1994
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.5M
93.1M
IPO Year
1996
1995

Fundamental Metrics

Financial Performance
Metric
VATE
ICCC
Price
$7.86
$9.98
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
89.3K
15.9K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
53.85
EPS
N/A
0.41
Revenue
$1,246,000,000.00
$26,493,169.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$23.54
Revenue Growth
12.55
51.64
52 Week Low
$3.75
$4.52
52 Week High
$21.30
$12.10

Technical Indicators

Market Signals
Indicator
VATE
ICCC
Relative Strength Index (RSI) 42.01 37.43
Support Level $6.41 $9.55
Resistance Level $8.20 $10.75
Average True Range (ATR) 0.42 0.24
MACD 0.07 -0.01
Stochastic Oscillator 32.53 22.67

Price Performance

Historical Comparison
VATE
ICCC

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: